Stereax Commercial ProgressQualification of manufacturing at Cirtec and delivery of M300 cells shows the company is moving from R&D to early production. This reduces scale-up execution risk, creates initial product revenues (cathode purchase orders and NRE paths) and establishes a durable route to recurring commercial income as volumes ramp.
Goliath Prototyping & Pilot Scale-upValidated 2Ah cells and shipment of automated pilot-line 10Ah prototypes to OEMs materially de-risks large-format development. Demonstrated pilot manufacturability and customer evaluation create a credible path to licensing or scale, supporting long-term commercialization if evaluations convert to deals.
IP And Asset-light Go-to-marketA diversified, asset-light licensing model combined with a 78-patent portfolio provides structural advantages: it protects technology, enables scalable revenue without heavy capex, and allows Ilika to monetise innovations via partners, preserving margin potential and limiting direct factory investment risk.